

Anaphylaxis (Immunology) - Drugs in Development, 2021

<https://marketpublishers.com/r/A08203F540B4EN.html>

Date: September 2021

Pages: 67

Price: US\$ 2,000.00 (Single User License)

ID: A08203F540B4EN

Abstracts

Anaphylaxis (Immunology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Drugs In Development, 2021, provides an overview of the Anaphylaxis (Immunology) pipeline landscape. Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical

stages comprises 2 molecules, respectively.

Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).

The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Anaphylaxis - Overview

Anaphylaxis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anaphylaxis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaphylaxis - Companies Involved in Therapeutics Development

Aquestive Therapeutics Inc

ARS Pharmaceuticals Inc

BioArdis LLC

Bryn Pharma LLC

G2B Pharma Inc

Hoth Therapeutics Inc

JDP Therapeutics Inc

MannKind Corp

Merck & Co Inc

Pharmacin BV

PIMS-E

Shenox Pharmaceuticals LLC

Anaphylaxis - Drug Profiles

AQST-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
HLK-0006 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
HT-KIT - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
JDP-207 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Monoclonal Antibody to Antagonize FcγR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Monoclonal Antibody to Antagonize FcγRIIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description

Mechanism Of Action

R&D Progress

SHX-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize MRGPRX2 for Anaphylaxis, Asthma, Inflammation and

Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-499 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anaphylaxis - Dormant Projects

Anaphylaxis - Product Development Milestones

Featured News & Press Releases

Mar 25, 2021: Aquestive Therapeutics provides update on its prodrug candidate AQST-109 at R&D event

Mar 25, 2021: Aquestive Therapeutics provides update on its prodrug candidate AQST-108 at R&D event

Mar 05, 2021: Aquestive Therapeutics to host investor & analyst virtual epinephrine drug delivery R&D event on March 25 at 9:00 a.m. ET

Nov 30, 2020: Recordati: Market authorization application for ARS-1 (epinephrine nasal spray) accepted by European Medicines Agency

Oct 29, 2020: Insignis Therapeutics and HLK Pharmacin receive FDA IND clearance to initiate a phase 1 trial with IN-001 for oral anaphylaxis treatment

Aug 20, 2020: Aquestive Therapeutics initiates Phase 1 Pharmacokinetic trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in development for treatment of allergic reactions including anaphylaxis

Aug 10, 2020: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including anaphylaxis

Jul 13, 2020: ARS Pharmaceuticals announces new patent on ARS-1 (epinephrine nasal spray)

Jun 29, 2020: Aquestive Therapeutics files IND for pharmacokinetic clinical trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for anaphylaxis treatment

Jun 10, 2020: Bryn Pharma announces the Publication of positive results from its Intranasal Epinephrine Preclinical Study program In three Peer-Reviewed Scientific Journals

May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intranasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors

Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodynamic effects of intranasal Epinephrine to intramuscular Epinephrine in adults

Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting

Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for anaphylaxis treatment

Nov 10, 2019: Bryn Pharma Research on Epinephrine Nasal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Anaphylaxis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, 2021
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, 2021
Anaphylaxis - Pipeline by BioArdis LLC, 2021
Anaphylaxis - Pipeline by Bryn Pharma LLC, 2021
Anaphylaxis - Pipeline by G2B Pharma Inc, 2021
Anaphylaxis - Pipeline by Hoth Therapeutics Inc, 2021
Anaphylaxis - Pipeline by JDP Therapeutics Inc, 2021
Anaphylaxis - Pipeline by MannKind Corp, 2021
Anaphylaxis - Pipeline by Merck & Co Inc, 2021
Anaphylaxis - Pipeline by Pharmacin BV, 2021
Anaphylaxis - Pipeline by PIMS-E, 2021
Anaphylaxis - Pipeline by Shenox Pharmaceuticals LLC, 2021
Anaphylaxis - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Anaphylaxis, 2021
- Number of Products under Development by Companies, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Molecule Types, 2021
- Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Anaphylaxis (Immunology) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/A08203F540B4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A08203F540B4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970